Niagen Bioscience (NASDAQ:NAGE) Issues Quarterly Earnings Results

Niagen Bioscience (NASDAQ:NAGE) announced its earnings results on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01, FiscalAI reports. Niagen Bioscience had a net margin of 14.29% and a return on equity of 23.63%. The company had revenue of $31.47 million for the quarter.

Niagen Bioscience Stock Performance

Shares of NAGE stock traded down $0.07 on Friday, hitting $4.13. 835,541 shares of the stock traded hands, compared to its average volume of 1,076,542. The firm’s 50-day moving average price is $4.74 and its two-hundred day moving average price is $5.82. The stock has a market capitalization of $328.53 million, a PE ratio of 19.64 and a beta of 2.17. Niagen Bioscience has a twelve month low of $4.04 and a twelve month high of $14.69.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen cut shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Canaccord Genuity Group lowered their target price on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NAGE. Vanguard Group Inc. acquired a new position in shares of Niagen Bioscience during the 3rd quarter valued at about $37,522,000. SteelPeak Wealth LLC acquired a new position in Niagen Bioscience in the first quarter valued at about $14,875,000. Arrowstreet Capital Limited Partnership acquired a new position in Niagen Bioscience in the third quarter valued at about $13,405,000. UBS Group AG acquired a new position in Niagen Bioscience in the third quarter valued at about $11,160,000. Finally, Qube Research & Technologies Ltd acquired a new position in Niagen Bioscience in the third quarter valued at about $8,175,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.